HOME › Research Insight › Major Players in the NGS Market Consider New Product Launch as the Key Strategy to Expand Their Global Footprint in the Market
Major Players in the NGS Market Consider New Product Launch as the Key Strategy to Expand Their Global Footprint in the Market
The global NGS market is highly consolidated with top two players, Illumina and Thermo Fisher (Life Technologies) occupying more than 90% of the pie (2013). Illumina led the market with its flagship NGS platforms such as HiSeq Series, GA IIx, and MiSeq. In 2014, it launched two new platforms HiSeq X Ten and NextSeq 500 which are poised to grow at CAGR of more than 20% in the coming years. It also provides reagents like TruSeq sample preparation kits, TruSeq SBS Sequencing kit, and other sequencing consumables. It also offers sequencing services such as whole genome sequencing, human whole exome, de novo sequencing, custom targeted resequencing, gene expression using random primed RNA sampling, and other related services. It also has a global presence with more than 50% of revenue generated from the U.S. and more than one-fourth from Europe. The market share of Illumina is estimated to increase by 2020, driven primarily by MiSeq, HiSeq X Ten and NextSeq 500 platforms, sales of consumables and increased service contract revenue as a result of growing installed base of instruments.
Illumina market revenues will be driven by the SBS technology platforms which are in high demand due to wide applications and its usage for both single read and pair end libraries.
In the next-generation sequencing market, companies focus on the strategy of new product launches to grow; this strategy accounted for half of the total number of growth strategies. Driven by advanced research and engineering activities, innovation in existing technologies, curiosity for a vast range of innovative platforms, and increased demand for highly compatible all-inclusive solutions have forced companies to focus on product launches. This strategy was adopted by players to provide high performance and robust technologies for sequencing to ensure explorative genomic research. It was also implemented to unlock novel diverse applications with the use of a single platform. The significant players adopting this strategy include Illumina, Inc (U.S.), Thermo Fisher Scientific (U.S.), Agilent Technologies, Inc (U.S.), Pacific Biosciences (U.S.), DNASTAR, INC (U.S.), 454 Life Sciences Corporation (U.S.), PerkinElmer, Inc (U.S.), GATC Biotech AG (Germany) and CLC bio (a member of QIAGEN). For example, in January 2014, Illumina unveiled two new sequencing platforms—the HiSeq X Ten sequencing system to study genotypic variations in a human population and the NextSeq 500 sequencing system that offers high-throughput performance in an affordable desktop form. NextSeq 500 will enable researchers to perform the most popular sequencing applications in less than a day. These new launches helped to expand the company’s sequencing product line. Illumina also launched multiple sequencing panels for cancer research which is the major focus of research currently.
Next Generation Sequencing (NGS) Market by Platforms (Illumina HiSeq, MiSeq, HiSeqX Ten, NextSeq 500,Thermo Fisher Ion Proton/PGM), Bioinformatics (Exome Sequencing, RNA-Seq, ChIP-Seq), Technology (SBS, SMRT) & by Application (Diagnostics, Personalized Medicine) – Global Forecast to 2020
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252